Target intelligence / Profile preview

Immunoglobulin kappa variable 1-33 (IGKV1-33)

Target
IGKV1-33
Molecular classification
Immunoglobulin variable region, Immunoglobulin light chain, Antibody, Other (not a GPCR, ion channel, enzyme, transporter, or transcription factor)
01

Overview

Immunoglobulin kappa variable 1-33 is part of the variable region of the human immunoglobulin kappa light chain, which, combined with the variable heavy chain domain, forms the antigen-binding site of antibodies. These regions are assembled by V-(D)-J recombination and can undergo somatic hypermutation, enabling affinity maturation in response to antigen exposure. Their primary function is to contribute to antigen recognition and diversity in humoral immunity, but as isolated domains, they are not therapeutic targets on their own. The requested target "immunoglobulin kappa variable 1/OR-2" is not a standard or recognized entry, and appears to be incorrect or misnamed. The closest validated targets are members of the immunoglobulin kappa variable family, e.g., IGKV1-33.

Other names
Ig kappa chain V-I region AUIg kappa chain V-I region KaKV133_HUMANP01594 (UniProt)IGKV1-33
02

Biological functions

Antigen bindingImmune response (component of humoral immunity)Facilitation of B cell activation and clonal expansion
03

Disease associations

Cancer (especially lymphoid malignancies with abnormal immunoglobulin rearrangements)Infection (regions contribute to adaptive immune responses)Other (autoimmunity, paraproteinemias)
04

Biomarkers

Clonality assessment in lymphoproliferative disease (immunoglobulin gene rearrangement analysis)Serum/urine paraprotein detection in plasma cell dyscrasias

Beyond the preview

Go deeper on Immunoglobulin kappa variable 1-33 (IGKV1-33).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa variable 1-33 (IGKV1-33).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call